What if the cure for obesity were hiding in a snake's blood? That's the surprising lead being explored by a team of American researchers who have just published a major finding: a molecule naturally present in the blood of the Burmese python is capable of significantly reducing appetite in obese mice, without triggering the side effects that plague current anti-obesity medications.

The python, a metabolic marvel

The Burmese python (Python bivittatus) is an animal with extraordinary physiological abilities. Capable of swallowing prey up to 25% of its own body weight, it can then fast for several consecutive months without losing muscle or developing metabolic disorders. Throughout this time, its body remains in perfect health.

This remarkable ability caught the attention of researchers at the University of Colorado Boulder (CU Boulder), working alongside teams from Stanford University and Baylor University. Their starting question: what biochemical mechanism allows the python to handle extreme cycles of feeding and fasting without harmful consequences?

The pTOS molecule: an unexpected discovery

By analyzing python blood immediately after a large meal, scientists identified a notable spike in a previously little-studied molecule: para-tyramine-O-sulfate, or pTOS. This molecule is the product of a remarkably simple chain of biochemical transformations:

• The digestive tract releases tyrosine, an amino acid found in animal proteins.
• Gut bacteria convert tyrosine into tyramine.
• The liver then transforms tyramine into pTOS.
• This compound travels to the brain, where it acts on the hypothalamus, the area responsible for appetite regulation.

In other words, the python naturally secretes — after every meal — a molecule that tells it: "stop, that's enough." A powerful and efficient satiety signal, arising directly from digestion.

Impressive results in mice

To test the effects of pTOS in mammals, researchers administered the molecule to obese mice. The results, published in the journal Nature Metabolism on March 19, 2026, are encouraging: treated animals spontaneously reduced their food intake and lost an average of 9% of their body weight. Unlike other substances tested in this field, pTOS did not affect basal energy metabolism, organ size, or muscle mass.

This last point is what makes the discovery so significant: muscles are preserved. A considerable advantage over existing medications, some of which are associated with problematic lean mass loss.

A key advantage over GLP-1 drugs

In recent years, GLP-1 analogues — including Ozempic (semaglutide) and Wegovy — have revolutionized obesity treatment. These drugs, initially developed for type 2 diabetes, enable significant weight loss. But they come with their share of drawbacks: nausea, vomiting, abdominal pain, slowed gastric emptying, and even cases of concerning muscle loss.

pTOS takes a radically different route. Where GLP-1 drugs primarily act on the pancreas and stomach, pTOS directly targets the brain via the hypothalamus. In experiments on mice, no gastrointestinal side effects were observed. A potentially major difference for the millions of patients who abandon their current treatments due to adverse effects.

"We found a molecule that speaks directly to the brain to say the body is full, without going through the pathways that cause digestive discomfort," the CU Boulder researchers summarized.

Toward a human treatment?

The road is still long before a pTOS-based human treatment is available in pharmacies. For now, experiments are limited to mouse models, and clinical trials in humans have not yet begun. However, the researchers have already taken steps forward: they founded a startup, Arkana Therapeutics, tasked with translating these findings into concrete medical applications.

The molecule has several advantages for pharmaceutical development: it is natural, derived from a simple metabolic pathway (and therefore potentially reproducible in the lab), and its mechanism of action is well identified. These characteristics should in theory facilitate its optimization and pharmaceutical formulation.

The gut microbiome: keystone of the discovery

One particularly interesting aspect of this research lies in the central role played by the gut microbiome. Without gut bacteria converting tyrosine into tyramine, there is no pTOS. This discovery adds a new dimension to our understanding of the link between gut flora, the brain, and weight regulation — an axis researchers call the gut-brain axis.

These data reinforce the idea that the microbiome is not just a player in digestion, but a true metabolic partner, capable of influencing appetite and eating behaviors through chemical signals. Understanding this axis could open other therapeutic avenues still unsuspected.

A breakthrough in the fight against obesity

Obesity today affects more than one billion people worldwide, according to the latest WHO data. Despite recent advances with GLP-1 drugs, many patients cannot benefit from these treatments due to their side effects, high cost, or medical contraindications. Finding new molecules acting through different mechanisms is therefore a global public health priority.

The discovery of pTOS is part of a broader trend: drawing inspiration from nature — and particularly animals with extreme metabolisms — to find solutions for human diseases. After lizard venom (which inspired the GLP-1s themselves, derived from exenatide of the Gila monster), the snake now enters the scene.

Nature, it seems, has not finished surprising us.